Literature review of small B-cell lymphoma with plasmacytic differentiation
Keywords:
-Abstract
-
Downloads
References
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. Lyon (France):IARC;2017.
Sukpanichnant S. Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. Hum Pathol. 2004;35:224-30.
Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K, et al. Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. Hematol Oncol. 2018;36:28-36.
Ponzoni M, Ferrerib AJ. Bacteria associated with marginal zone lymphomas. Best Pract Res Clin Haematol. 2017;30:32-40.
Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: associated autoimmunity and auto-immune disorders. Best Pract Res Clin Haematol. 2017;30:65-76.
Chacón JI, Mollejo M, Muñoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648-54.
Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950-6.
Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, et al. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1999;17:2486-92.
Harmon CM, Smith LB. B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation. Surg Pathol Clin. 2016;9:11-28.
Piris MA, Onaindía A, Mollejo M. Splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30:56-64.
Falini B, Agostinelli C, Bigerna B, Pucciarini A, Pacini R, Tabarrini A, et al. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology. 2012;61:930-41.
Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122:1286-94.
Molina TJ, Lin P, Swerdlow SH, Cook JR. Marginal zone lymphomas with plasmacytic differentiation and related disorder. Am J Clin Pathol. 2011;136:211-25.
Mullen EC, Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs. 2007;11:87-95.
Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol. 2007;60:1378-83.
Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer. 1996;77:2604-13.
Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst. 2010;102:557-67.
Xie Y, Vallangeon B, Liu X, Lagoo AS. Plasmacytic or lymphoplasmacytic infiltrate in lymph nodes: diagnostic approach and differential considerations. Indian J Pathol Microbiol. 2016;59:446-56.
Swerdlow SH, Kuzu I, Dogan A, Dirnhofer S, Chan JK, Sander B, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468:259-75.
Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström’s macroglobulinemia.Mod Pathol. 2009;22:807-16.
Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121:2051-8.
Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121:2522-8.
Hamadeh F, MacNamara SP, Aguilera NS, Swerdlow SH, Cook JR. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Mod Pathol. 2015;28:564-74.
Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121:4504-11.
Sukpanichnant S, Pinijvechagarn M, Poungvarin N. MYD88 L265P mutation status in small B-cell lymphoma with plasmacytic differentiation and extensive amyloid deposition. J Hematol Transfus Med. 2020;30:369-78.
Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström’s Macroglobulinemia. N Engl J Med.2015;373:584-6.
Schmidt J, Federmann B, Schindler N, Steinhilber J, Bonzheim I, Fend F, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;169:795-803.
Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136:80-6.
Kutálková K, Sedlaříková L, Adam Z, Ševčíková S. Gene mutations connected to Waldenstöm macroglobulinemia. Vnitr Lek.
;62:40-3.
Rivera AI, Li MM, Beltran G, Krause JR. Trisomy 4 as the sole cytogenetic abnormality in a Waldenström macroglobulinemia.
Cancer Genet Cytogenet. 2002;133:172-3.
Terré C, Nguyen-Khac F, Barin C, Mozziconacci MJ, Eclache V, Léonard C, et al. Trisomy 4, a new chromosomal abnormality in Waldenström’s macroglobulinemia: a study of 39 cases. Leukemia.2006;20:1634-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
